MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 9, Pages e105919
Publisher
Public Library of Science (PLoS)
Online
2014-09-16
DOI
10.1371/journal.pone.0105919
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells
- (2013) Magali Humbert et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- EphB4 as a therapeutic target in mesothelioma
- (2013) Ren Liu et al. BMC CANCER
- Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
- (2013) R. Katayama et al. CANCER RESEARCH
- Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET
- (2013) C. Basilico et al. CLINICAL CANCER RESEARCH
- Targeting mTOR to Overcome Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer Cells
- (2013) Shi-Jiang Fei et al. PLoS One
- Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
- (2012) B. Markman et al. ANNALS OF ONCOLOGY
- Exploratory analysis of activation of PTEN–PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM)
- (2012) S. Cedrés et al. LUNG CANCER
- PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies
- (2012) Lise Willems et al. Current Oncology Reports
- Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy
- (2011) Cheng-Xiong Xu et al. CANCER BIOLOGY & THERAPY
- Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197
- (2011) Sudharshan Eathiraj et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Temsirolimus Inhibits Malignant Pleural Mesothelioma Growth In Vitro and In Vivo: Synergism with Chemotherapy
- (2011) Mir Alireza Hoda et al. Journal of Thoracic Oncology
- GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
- (2011) J. J. Wallin et al. MOLECULAR CANCER THERAPEUTICS
- The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer
- (2011) Jatin Roper et al. PLoS One
- Update on Malignant Pleural Mesothelioma
- (2011) Nicholas Campbell et al. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
- In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs
- (2011) Neelesh Sharma et al. Therapeutic Advances in Medical Oncology
- Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma
- (2010) Sheelu Varghese et al. CANCER
- The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma
- (2010) D. C. Cho et al. CLINICAL CANCER RESEARCH
- ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity
- (2010) N. Munshi et al. MOLECULAR CANCER THERAPEUTICS
- Phosphorylation of focal adhesion kinase on tyrosine 194 by Met leads to its activation through relief of autoinhibition
- (2010) T-H Chen et al. ONCOGENE
- Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
- (2009) P Cao et al. BRITISH JOURNAL OF CANCER
- Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells
- (2009) Koji Kawaguchi et al. CARCINOGENESIS
- Activation of native TRPC1/C5/C6 channels by endothelin-1 is mediated by both PIP3and PIP2in rabbit coronary artery myocytes
- (2009) Sohag N. Saleh et al. JOURNAL OF PHYSIOLOGY-LONDON
- PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription
- (2009) Rajani Kanteti et al. LABORATORY INVESTIGATION
- NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
- (2009) T.-J. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
- (2008) R. Jagadeeswaran et al. CANCER RESEARCH
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
- (2008) S. Yano et al. CANCER RESEARCH
- The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma
- (2008) Philipp Baumann et al. EXPERIMENTAL CELL RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started